CIBA AREDIA SHOWS SIX-MONTH DIFFERENCE IN MEDIAN TIME TO FIRST SKELETAL EVENT IN BREAST CANCER PATIENTS; FDA COMMITTEE RECOMMENDS BREAST CANCER USE
Executive Summary
Ciba-Geigy's Aredia treatment of breast cancer patients shows a 13-month median time to first skeletal-related events excluding hypercalcemia, compared to seven months for placebo, according to Ciba's analysis of a 382-patient pivotal trial presented June 13 at FDA's Oncologic Drugs Advisory Committee review of the bisphosphonate drug.